Literature DB >> 14673393

Musculoskeletal features of disorders of lipid metabolism and multicentric reticulohistiocytosis.

Thomas Bardin1.   

Abstract

PURPOSE OF REVIEW: Musculoskeletal features of hyperlipidemia are well known, although rarely encountered by rheumatologists. New data have been collected on the beneficial and adverse effects of lipid-lowering drugs, which are of interest to rheumatologists. Multicentric reticulohistiocytosis is a rare systemic disorder of which joint involvement is an important and frequent feature. Recent advances in its pathophysiology and management have been made. RECENT
FINDINGS: Little has been added to the knowledge about the musculoskeletal features of hyperlipidemia in the recent literature. In contrast, the interest in fenofibrate for treating hyperuricemia in patients with lipid disorders or in those intolerant of allopurinol has been further supported. Muscle toxicity of statins continue to retain attention, and the ability of these drugs to induce low-grade myopathy, without increasing serum creatine kinase, has been defended. Multicentric reticulohistiocytosis has been the subject of a number of articles, including reports on the efficacy of cyclosporine and of etanercept in one patient each.
SUMMARY: Several issues of therapeutic importance are discussed in this brief review.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14673393     DOI: 10.1097/00002281-200401000-00014

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  2 in total

Review 1.  Cardiac engagement in multicentric reticulohistiocytosis: report of a case with fatal outcome and literature review.

Authors:  Maurizio Benucci; Antonio Sulla; Mariangela Manfredi
Journal:  Intern Emerg Med       Date:  2008-02-12       Impact factor: 3.397

Review 2.  Multicentric reticulohistiocytosis: a rare yet challenging disease.

Authors:  Arshia D Islam; Stanley M Naguwa; Gurtej S Cheema; John C Hunter; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.